It may take some time for the KNACK to become part of your daily life. SO PRACTICE THE KNACK UNTIL IT BECOMES A HABIT. SO IT BECOMES AUTOMATIC !

December 16, 2025 Is the era within which a TURP was performed associated with differences in reoperation rates, specific surgical side effects, or the requirement for BPH medicat ...

Daniel Spratt and Alicia Morgans discuss clinical outcomes of patients with Gleason score 9-10 prostate cancer after definitive treatment. Long-term Survival in Men with Gleason Score 9-10 Treated ...

ASCO 2025 Press Releases Johnson & Johnson Leads with First PARP Inhibitor Combo to Improve Efficacy in Patients with HRR-altered mCSPC ImmunityBio Receives FDA Expanded Access Authorization for ...

Zachary Klaassen speaks with Jie Luo about his Prostate Cancer Foundation Young Investigator Award work on androgen receptor enhanceosomes in prostate cancer. Dr. Luo explains that enhanceosomes are ...

ESMO 2024, Prostate Cancer, transdermal estradiol, LHRH agonists, Transdermal Estradiol Versus LHRH Agonists, Androgen Suppression in M0 Prostate Cancer, STAMPEDE trial.

(UroToday.com) In this presentation, Dr. Fred Saad presented results of the PROpel study. PROpel is a randomized phase III trial of abiraterone plus olaparib versus abiraterone plus placebo as ...

Andrew Hahn discusses the LenCabo study, a randomized phase 2 trial comparing lenvatinib plus everolimus versus cabozantinib for metastatic clear cell renal cell carcinoma progressing on PD-1 ...

Is Primary Retroperitoneal Lymph Node Dissection the Way Forward for Patients with Testicular Seminoma and Limited Retroperitoneal Metastases? - Beyond the Abstract ...

ESMO 2025 CPS score and tumor nephrectomy in the SUNNIFORECAST trial, ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer.

ESMO 2025 final results of PRESTO (AFT-19), phase III trial of combined androgen blockade in patients with high-risk, biochemically relapsed prostate cancer.

ESMO 2025, Muscle-Invasive Bladder Cancer (MIBC), Perioperative Enfortumab Vedotin plus Pembrolizumab, KEYNOTE-905 trial, T2-T4aN0M0, T1-T4aN1M0.